Clinical relevance of advances in genetics and pharmacogenetics of IBD.

Crohn's disease and ulcerative colitis result from an inappropriate response of the mucosal immune system to the normal enteric flora in a genetically susceptible individual. During the past decade, exciting progress has been made in our understanding of the contribution of genetics to inflammatory bowel disease susceptibility and phenotype. This article reviews recent advances in the genetics of inflammatory bowel disease and explores how they might impact on clinical practice. Current knowledge of the genetic basis for disease susceptibility, phenotype, and response to therapy is explored and the factors currently limiting the translation of this knowledge to clinical practice is discussed.

[1]  Laurent Beaugerie,et al.  High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. , 2004, Gastroenterology.

[2]  K. Peters,et al.  CARD15 and Crohn's disease , 2004, Journal of gastroenterology and hepatology.

[3]  Judy H. Cho,et al.  MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. , 2003, American journal of human genetics.

[4]  T. Ahmad,et al.  The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. , 2003, Tissue antigens.

[5]  B. Bonaz,et al.  Drug interaction between infliximab and azathioprine in patients with Crohn's disease , 2003, Alimentary pharmacology & therapeutics.

[6]  S. Cheung,et al.  Mistaken identity: misclassification of TPMT phenotype following blood transfusion. , 2003, European journal of gastroenterology & hepatology.

[7]  M. Dubinsky.  Monitoring of AZA/6-MP treatment in children with IBD is necessary. , 2003, Inflammatory bowel diseases.

[8]  Judy H. Cho,et al.  Expression of NOD2 in Paneth cells: a possible link to Crohn’s ileitis , 2003, Gut.

[9]  Judy H. Cho,et al.  Defining Complex Contributions of NOD2/CARD15 Gene Mutations, Age at Onset, and Tobacco Use On Crohn's Disease Phenotypes , 2003, Inflammatory bowel diseases.

[10]  J. Silver.  The importance of penetration. , 2003, Inflammatory bowel diseases.

[11]  H. Zouali,et al.  Association between mutations in the CARD15 (NOD2) gene and Crohn's disease in Israeli Jewish patients , 2003, American journal of medical genetics. Part A.

[12]  M. Chamaillard,et al.  Nods, Nalps and Naip: intracellular regulators of bacterial‐induced inflammation , 2003, Cellular microbiology.

[13]  Changqing Zheng,et al.  Progress in searching for susceptibility gene for inflammatory bowel disease by positional cloning. , 2003, World journal of gastroenterology.

[14]  D. Jewell,et al.  Genotype-phenotype analysis of the Crohn’s disease susceptibility haplotype on chromosome 5q31 , 2003, Gut.

[15]  M. Daly,et al.  IBD5 is a general risk factor for inflammatory bowel disease: replication of association with Crohn disease and identification of a novel association with ulcerative colitis. , 2003, American journal of human genetics.

[16]  S. Davies,et al.  Crohn's disease and the NOD2 gene: a role for paneth cells. , 2003, Gastroenterology.

[17]  D. Jewell,et al.  NOD2/CARD15 gene polymorphisms and Crohn's disease in the Chinese population , 2003, Alimentary pharmacology & therapeutics.

[18]  L. Rodrigo,et al.  TNF-alpha -308A promoter polymorphism is associated with enhanced TNF-alpha production and inflammatory activity in Crohn's patients with fistulizing disease. , 2003, The American journal of gastroenterology.

[19]  J. Satsangi,et al.  Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? , 2003, Gut.

[20]  J. Belaiche,et al.  Early development of stricturing or penetrating pattern in Crohn’s disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype , 2003, Gut.

[21]  L. Cardon,et al.  Analysis of the IBD5 locus and potential gene-gene interactions in Crohn’s disease , 2003, Gut.

[22]  D. Podolsky,et al.  CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. , 2003, Gastroenterology.

[23]  V. Konda,et al.  Do inflammatory bowel disease (IBD) patients want genetic testing , 2003 .

[24]  P. Rosenstiel,et al.  TNF-α and IFN-γ regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells ☆ ☆☆ ★ ★★ ♢ , 2003 .

[25]  M. Färkkilä,et al.  CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn’s disease , 2003, Gut.

[26]  Tariq Ahmad,et al.  Haplotype-specific linkage disequilibrium patterns define the genetic topography of the human MHC. , 2003, Human molecular genetics.

[27]  M. Chamaillard,et al.  Nod2 Is a General Sensor of Peptidoglycan through Muramyl Dipeptide (MDP) Detection* , 2003, The Journal of Biological Chemistry.

[28]  P. McKeigue,et al.  Problems of reporting genetic associations with complex outcomes , 2003, The Lancet.

[29]  J. Hugot,et al.  Gene–environment interaction modulated by allelic heterogeneity in inflammatory diseases , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  E. Kuipers,et al.  CARD15 and Crohn's Disease: Healthy Homozygous Carriers of the 3020insC Frameshift Mutation , 2003, American Journal of Gastroenterology.

[31]  C. O'Morain,et al.  Association of NOD2 with Crohn's Disease in a homogenous Irish population , 2003, European Journal of Human Genetics.

[32]  S. Foster,et al.  Host Recognition of Bacterial Muramyl Dipeptide Mediated through NOD2 , 2003, The Journal of Biological Chemistry.

[33]  Min Huang,et al.  Interactions of Herbs with Cytochrome P450 , 2003, Drug metabolism reviews.

[34]  N. O’Callaghan,et al.  CARD15/NOD2 Risk Alleles in the Development of Crohn's Disease in the Australian Population , 2003, Annals of human genetics.

[35]  Lucia Mirea,et al.  A Population- and Family-Based Study of Canadian Families Reveals Association of HLA DRB1*0103 With Colonic Involvement in Inflammatory Bowel Disease , 2003, Inflammatory bowel diseases.

[36]  J. Silver,et al.  Variation at NOD2/CARD15 in familial and sporadic cases of Crohn’s disease in the Ashkenazi Jewish population , 2002 .

[37]  Yasunori Ogura,et al.  Induction of Nod2 in Myelomonocytic and Intestinal Epithelial Cells via Nuclear Factor-κB Activation* , 2002, The Journal of Biological Chemistry.

[38]  J. Belaiche,et al.  Behaviour of Crohn's disease according to the Vienna classification - Reply , 2002 .

[39]  J. Hampe,et al.  Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. , 2002, Pharmacogenetics.

[40]  Yusuke Nakamura,et al.  Absence of mutation in the NOD2/CARD15 gene among 483 Japanese patients with Crohn's disease , 2002, Journal of Human Genetics.

[41]  D. Jewell,et al.  Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. , 2002, Gastroenterology.

[42]  A. Zinsmeister,et al.  N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis. , 2002 .

[43]  J. Belaiche,et al.  NOD2/CARD15 does not influence response to infliximab in Crohn's disease. , 2002, Gastroenterology.

[44]  M. Daly,et al.  CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. , 2002, American journal of human genetics.

[45]  A. Macpherson,et al.  In siblings with similar genetic susceptibility for inflammatory bowel disease, smokers tend to develop Crohn's disease and non-smokers develop ulcerative colitis , 2002, Gut.

[46]  T. Hibi,et al.  Lack of common NOD2 variants in Japanese patients with Crohn's disease. , 2002, Gastroenterology.

[47]  F. Carbonnel,et al.  Long-Term Evolution of Disease Behavior of Crohn's Disease , 2002, Inflammatory bowel diseases.

[48]  J. Belaiche,et al.  A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism , 2002 .

[49]  D. Jewell,et al.  60 P The 5q31/IBD5 risk haplotype is associated with overall susceptibility to Crohn's disease and determines perianal phenotype , 2002 .

[50]  C. Peterson,et al.  Differences Between Children and Adults in Thiopurine Methyltransferase Activity and Metabolite Formation During Thiopurine Therapy: Possible Role of Concomitant Methotrexate , 2002, Therapeutic drug monitoring.

[51]  C. Folwaczny,et al.  The c-insertion mutation of the NOD2 gene is associated with fistulizing and fibrostenotic phenotypes in Crohn's disease. , 2002, Gastroenterology.

[52]  M. Vatn,et al.  Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study , 2002, The Lancet.

[53]  C. Kelly,et al.  P‐Glycoprotein‐170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes , 2002, Alimentary pharmacology & therapeutics.

[54]  R. Myers,et al.  Candidate-gene approaches for studying complex genetic traits: practical considerations , 2002, Nature Reviews Genetics.

[55]  D. Sachar.  Genomics and phenomics in Crohn's disease. , 2002, Gastroenterology.

[56]  Alastair Forbes,et al.  The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. , 2002, Gastroenterology.

[57]  C. O'Morain,et al.  CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. , 2002, American journal of human genetics.

[58]  S. Targan,et al.  6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. , 2002, Gastroenterology.

[59]  B. Alizadeh,et al.  CARD15 gene and the classification of Crohn's disease , 2002, Immunogenetics.

[60]  T. Ahmad,et al.  The molecular classification of the clinical manifestations of Crohn's disease. , 2002, Gastroenterology.

[61]  G. Novelli,et al.  3020insC mutation within the NOD2 gene in Crohn's disease: frequency and association with clinical pattern in an Italian population. , 2002, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[62]  Y. Ogura,et al.  Nods: a family of cytosolic proteins that regulate the host response to pathogens. , 2002, Current opinion in microbiology.

[63]  J. Belaiche,et al.  Inflammatory Bowel Disease A Positive Response to Infliximab in Crohn Disease: Association with a Higher Systemic Inflammation Before Treatment But Not With -308 TNF Gene Polymorphism , 2002, Scandinavian journal of gastroenterology.

[64]  J. Belaiche,et al.  Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease , 2001, Gut.

[65]  K. Schulte,et al.  Genetic Determinants of IL-6 Expression Levels Do Not Influence Bone Loss in Inflammatory Bowel Disease , 2001, Digestive Diseases and Sciences.

[66]  J. Ioannidis,et al.  Replication validity of genetic association studies , 2001, Nature Genetics.

[67]  Sinead B. O'Leary,et al.  Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease , 2001, Nature Genetics.

[68]  A. Cox,et al.  The interleukin 1 receptor antagonist gene allele 2 as a predictor of pouchitis following colectomy and IPAA in ulcerative colitis. , 2001, Gastroenterology.

[69]  Judy H. Cho,et al.  The Nod2 Gene in Crohn's Disease: Implications for Future Research Into the Genetics and Immunology of Crohn's Disease , 2001, Inflammatory bowel diseases.

[70]  F. Carbonnel,et al.  Impact of cessation of smoking on the course of ulcerative colitis , 2001, American Journal of Gastroenterology.

[71]  S. Fisher,et al.  Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations , 2001, The Lancet.

[72]  J. Satsangi,et al.  The genetics of inflammatory bowel disease , 2001, Alimentary pharmacology & therapeutics.

[73]  Mourad Sahbatou,et al.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.

[74]  Judy H. Cho,et al.  A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease , 2001, Nature.

[75]  T. Bayless,et al.  Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease , 2001, Gut.

[76]  P. Dickman,et al.  Family history as a risk factor for colorectal cancer in inflammatory bowel disease. , 2001, Gastroenterology.

[77]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[78]  N. Camp,et al.  Association of the interleukin 1 receptor antagonist gene with ulcerative colitis in Northern European Caucasians , 2001, Gut.

[79]  S. Yamaoka,et al.  Nod2, a Nod1/Apaf-1 Family Member That Is Restricted to Monocytes and Activates NF-κB* , 2001, The Journal of Biological Chemistry.

[80]  D. Weeks,et al.  The IBD2 locus shows linkage heterogeneity between ulcerative colitis and Crohn disease. , 2000, American journal of human genetics.

[81]  A. Dignass,et al.  Genetic factors determine extent of bone loss in inflammatory bowel disease. , 2000, Gastroenterology.

[82]  W. Evans,et al.  Genetic Polymorphism of Thiopurine S-Methyltransferase: Molecular Mechanisms and Clinical Importance , 2000, Pharmacology.

[83]  D. Rubin,et al.  Smoking and inflammatory bowel disease. , 2000, European journal of gastroenterology & hepatology.

[84]  T. Bayless,et al.  Enhanced bioavailability of azathioprine compared to 6‐mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy , 2000, Alimentary pharmacology & therapeutics.

[85]  William C. Parks,et al.  Secretion of microbicidal α-defensins by intestinal Paneth cells in response to bacteria , 2000, Nature Immunology.

[86]  B. Bonaz,et al.  Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. , 2000, Gastroenterology.

[87]  E S Lander,et al.  Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. , 2000, American journal of human genetics.

[88]  T. Ashida,et al.  Expression of glucocorticoid receptor β in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis ☆ ☆☆ , 2000 .

[89]  C. Kumana,et al.  Association studies of genetic polymorphisms and complex disease , 2000, The Lancet.

[90]  S. Targan,et al.  Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. , 2000, Gastroenterology.

[91]  S. Targan,et al.  HLA class II haplotype associations with inflammatory bowel disease in Jewish (Ashkenazi) and non-Jewish caucasian populations. , 2000, Human immunology.

[92]  D. Jewell,et al.  Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. , 2000, Gastroenterology.

[93]  D. Jewell,et al.  A Simple Classification of Crohn's Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998 , 2000, Inflammatory bowel diseases.

[94]  P. Keeling,et al.  High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. , 2000, Gastroenterology.

[95]  N J Lynch,et al.  Linkage of inflammatory bowel disease to human chromosome 6p. , 1999, American journal of human genetics.

[96]  S. Targan,et al.  A genome-wide search identifies potential new susceptibility loci for Crohn's disease , 1999 .

[97]  Gen Tamiya,et al.  Complete sequence and gene map of a human major histocompatibility complex , 1999 .

[98]  P. Reitsma,et al.  HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis , 1999, Gut.

[99]  M. Vatn,et al.  Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. , 1999 .

[100]  J. Féher,et al.  IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease , 1999, Immunogenetics.

[101]  S. Targan,et al.  Linkage of Crohn’s disease to the major histocompatibility complex region is detected by multiple non-parametric analyses , 1999, Gut.

[102]  A. Peña,et al.  Genetic markers in clinically well defined patients with ulcerative colitis (UC) , 1999 .

[103]  M. Neurath,et al.  Cytokine Gene Transcription By NF‐κB Family Members in Patients with Inflammatory Bowel Disease , 1998 .

[104]  A. Ballinger,et al.  6-Mercaptopurine metabolism in Crohn’s disease , 1998, Gut.

[105]  P. Barnes,et al.  Anti-inflammatory actions of glucocorticoids: molecular mechanisms. , 1998, Clinical science.

[106]  H. Steinhart,et al.  Reliability of a Crohn's Disease Clinical Classification Scheme Based on Disease Behavior , 1998, Inflammatory bowel diseases.

[107]  G. Fakis,et al.  Expression of arylamine N-acetyltransferase in human intestine , 1998, Gut.

[108]  R. Weinshilboum,et al.  Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity. , 1998, The Journal of clinical investigation.

[109]  J. Beijnen,et al.  Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. , 1997, The Journal of clinical investigation.

[110]  A. Marshall,et al.  Getting the right drug into the right patient , 1997, Nature Biotechnology.

[111]  R. Weinshilboum,et al.  Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms , 1997, Clinical pharmacology and therapeutics.

[112]  J. Satsangi,et al.  Genetic markers may predict disease behavior in patients with ulcerative colitis. , 1997, Gastroenterology.

[113]  Griffin Jp.  The cost of adverse drug reactions. , 1997 .

[114]  P. Borst,et al.  Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[115]  G. Chrousos,et al.  Inhibition of mineralocorticoid activity by the β-isoform of the human glucocorticoid receptor , 1997, The Journal of Steroid Biochemistry and Molecular Biology.

[116]  J. Terwilliger,et al.  Two stage genome–wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12 , 1996, Nature Genetics.

[117]  Y. Théorêt,et al.  6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. , 1996, Gut.

[118]  D. Jewell,et al.  Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease , 1996, The Lancet.

[119]  Eric Lander Leonid Kruglyak.  Genetic dissection of complex traits , 1996, Nature Genetics.

[120]  W. Evans,et al.  Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. , 1996, American journal of human genetics.

[121]  Jean Weissenbach,et al.  Mapping of a susceptibility locus for Crohn's disease on chromosome 16 , 1996, Nature.

[122]  E. Lander,et al.  Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results , 1995, Nature Genetics.

[123]  P. Barnes.  Anti-inflammatory mechanisms of glucocorticoids. , 1995, Biochemical Society transactions.

[124]  W. Evans,et al.  Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. , 1995, Molecular pharmacology.

[125]  G. Chrousos,et al.  Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. , 1995, The Journal of clinical investigation.

[126]  R. Weinshilboum,et al.  Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. , 1995, British journal of clinical pharmacology.

[127]  J. Satsangi,et al.  Genetics of inflammatory bowel disease. , 1994, Gut.

[128]  G. Gyapay,et al.  A second-generation linkage map of the human genome , 1992, Nature.

[129]  R. Jorde,et al.  The incidence of ulcerative colitis in Northern Norway from 1983 to 1986. The Northern Norwegian Gastroenterology Society. , 1990, Scandinavian journal of gastroenterology.

[130]  R. Weinshilboum,et al.  Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia , 1990, The Lancet.

[131]  R. Weinshilboum,et al.  Thiopurine pharmacogenetics in leukemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6‐thioguanine nucleotide concentrations , 1987, Clinical pharmacology and therapeutics.

[132]  R. Weinshilboum,et al.  Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. , 1980, American journal of human genetics.

[133]  H. Watts,et al.  National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. , 1979, Gastroenterology.

[134]  Judy H. Cho,et al.  Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. , 2003, Gastroenterology.

[135]  U. Brinkmann,et al.  Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. , 2003, Gastroenterology.

[136]  Judy H. Cho,et al.  Significant role of genetics in IBD: the NOD2 gene. , 2003, Reviews in gastroenterological disorders.

[137]  J. Yamamoto-Furusho,et al.  Clinical and genetic heterogeneity in Mexican patients with ulcerative colitis. , 2003, Human immunology.

[138]  K. Huse,et al.  Haplotype structure and association to Crohn's disease of CARD15 mutations in two ethnically divergent populations , 2003, European Journal of Human Genetics.

[139]  J. Hampe,et al.  Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab , 2002, The Pharmacogenomics Journal.

[140]  A. Forbes,et al.  Pharmacogenomics of Response to Anti-Tumor Necrosis Factor Therapy in Patients with Crohn’s Disease , 2002, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[141]  B. Sikic,et al.  Effect of the multidrug resistance modulator valspodar on serum cortisol levels in rabbits , 1998, Cancer Chemotherapy and Pharmacology.

[142]  U. Meyer,et al.  Molecular mechanisms of genetic polymorphisms of drug metabolism. , 1997, Annual review of pharmacology and toxicology.

[143]  J. Lennard-jones,et al.  The prognosis of idiopathic proctitis. , 1977, Scandinavian journal of gastroenterology.